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 Antibiotic Goals 
• Promote bacteria death 
• Prevent the emergence of resistance 
• Avoid toxicity 
  
Underdosing 
 Increase in Volume of distribution 
 Increase in clearance 
Dose of Antibiotics 
  How much? 
Antibiotic must n t only attach to target but must occupy an 
adequate number of binding sites during a certain time 
That depends on drug concentration and time within the 
organism – the PK, and also on bacteria susceptibility – MIC 
Usually antibiotic concentration must be over 3-5 times MIC 
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Aminoglycosides 
Metronidazol 
Azithromycin 
Fluoroquinolones 
Glycopeptides 
Beta-lactams 
Carbapenems 
 
Time (hours) 
Concentration 
Cmax 
T>MIC 
Area under the concentration curve 
MIC 
Patterns of Antimicrobial Activity 
Mainly dependent of VD 
Mainly dependent of the Cl 
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Concentration and Volume of Distribution 
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Aminoglycoside 
Glycopeptide 
Fluoroquinolone 
Vd 15-20 liters 
Vd 80-200 liters 
Vd (L)=Dose (mg) 
            Conc (mg/L) 
 The apparent volume of distribution indicates into 
how large a volume the drug distributes if it were at the 
same concentration as that in plasma 
 
 Initial peak concentration is only dependent on dose 
and volume of distribution 
 
 Clearance indicates how much fluid is cleared of the 
drug per time 
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Individual variation 
Time (hours) 
Concentration 
Cmax 
MIC 
Pharmacokinetics of antibiotics for a given population 
MIC 
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Volume of Distribution 
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Drugs 
Lipophilic 
Drugs 
Volume 
Resuscitation 
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Nicolau Antimicrob Agents Chemother 1995;39:650 
Baral Am J Med.2003;114:194 
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Concentration (mg/L) 
Fast bactericidal activity depends on peak 
drug concentration 
Slower and independent of drug 
concentration (postantibiotic effect) 
Aminoglycosides antimicrobial activity 
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90% probability of resolution 
by day 7 if a Cmax/MIC of ≥ 
10 is achieved within the first 
48h of aminoglycoside 
therapy  
Kashuba Antimicrob Agents Chemother 1999 
N=78 Gram negative rods 
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Aminoglycosides 
Moore J Infect Dis 1987;155. 93 
Aminoglycosides antimicrobial activity 
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Barza M BMJ 1996;312:338 
Meta-analysis of 21 randomised trials; N=3091  
Multiple doses or large dose 
Large dose associated with a non-significant decrease in 
antibiotics failures (especially in Pseudomonas) 
  
 
 Large dose administration reduced the risk of nephrotoxicity 
  (fixed effects risk ratio 0.74 (0.54 to 1.00)).  
 
 There was no significant difference in ototoxicity between the two 
dosing regimens, 
 but the power of the pooled trials to detect a meaningful difference was low.  
 There was no significant difference in mortality 
Aminoglycosides antimicrobial activity 
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Gonçalves-Pereira Clin Microbiol Infect  2010;16:1258 
Pharmacokinetics / Pharmacodynamics 
First dose of Aminoglycosides 
Taccone Crit Care 2010;14:R53 
 Amikacin 
 
25mg/kg. Peak target 64 mg/L 
N=74; Vd=0.41l/kg 
 Gentamicin 
 
7.4mg/kg. Peak target 16 mg/L 
N=32; Vd=0.41l/kg 
No relationship with age, organ failure, SOFA or sepsis severity 
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Vd first dose  0,41 l/kg (±0,1) 
Gonçalves-Pereira Clin Microbiol Infect  2010;16:1258 
Hilmer Br J Clin Pharmacol 2011; 71: 224–231 
R2=0.058 
R2=0.016 
Pharmacokinetics / Pharmacodynamics 
First dose of Aminoglycosides 
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Time (hours) 
Concentration Cmax 
MIC 
Pharmacokinetics / Pharmacodynamics 
Aminoglycosides Pharmacokinetics 
 Pharmacodynamic parameter of efficacy: Peak/MIC 
 Toxicity (Renal accumulation): Trough concentration and interval 
Cmax 
Renal failure 
 
 
 
 
Renal proximal convoluted 
tubules; a saturable process  
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Antimicrob Agents Chemother 2011: 2528 
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Triginer Intensive Care Med 1990;16:303-306 
Dose of antibiotics 
  Aminoglycosides 
Progressive normalization of PK 
• Normalization of the increase in Vd 
and Cl (with sepsis resolution) 
 
• High antibiotic concentration 
 
 
Use of TDM – Peak and a second measurement between 16-20h 
  Linear PK and 1st order kinetics 
480mg. Peak (1h) – 18mg/dl; Trough (17h) 2mg/dl Vd=24,1L Cl=3,3ml/min 
  Recommended dose 480mg after 28h 
  Peak (2h) – 18mg/dl; Trough (16h) 2mg/dl Vd=20,3 Cl=3,2ml/min 
  Recommended dose 400mg after 27h 
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Clinically evaluable patients 
(n=53) 
57% success 
Moise P. Am J Health Syst Pharm 2000;57 (Suppl 2):S4–S9 
AUC/MIC ≤345 
(n=21) 
24% success 
AUC/MIC >345 
(n=32) 
78% success 
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AUIC >400 
AUIC <400 
P=0.0402 
 MIC>1 
Dose of antibiotics 
  Vancomycin 
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To achieve therapeutic concentrations rapidly loading doses 
are recommended 
Recommend giving high end of normal loading dose (or even higher 
dose) 
– Example: Vancomycin (normal patient Vd ~0.7 L/kg) 
• 100 kg septic shock patient 
 
   Am J Health-Syst Pharm 2009;66:82-98 
Hall. Am J Med. 2008; 121: 515–518 
Dose of antibiotics 
  Vancomycin 
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PK monitoring – Vancomycin 
N Vd (L) Vol (L) Increase 
Vancomycin 43 75 (81) 49 53.1% 
 DALI Data 
As presented in the 25th ESICM Congress 
N Cl (L/H) Vol (L/H) Increase Cr Cl (L/H) RRT 
Vancomycin 43 3.6 (3.9) 3.6 0 84 (46) 9 
Continuous 
Infusion (N=25) 
Intermittent 
(N=18) 
Trough 58% (Css>20) 42% (>15) 
AUC/MIC>400 88% 45% 
Cure 70% 58% 
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Therapeutic Drug Monitoring 
Vancomycin – Bolus dosing  
Measured concentrations were more often in therapeutic range when guided by 
TDM then by Moellering’s nomogram. 
 Out of Therapeutic Range 
   Peak  A-50% B-50% 
  Trough  A-0% B-43.8%  
  Dose/kg A – 19±0.5 mg B – 17±0.4 mg 
Pea Int J Antimicrob Agents 2002; 20: 326 
TDM 
Moellering’s Nomogram 
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Baptista Int J Antimicrob Agents 2012;39:420 
20ug/mL 
Cl Cr>130mL/min 
        Vs. 
Cl Cr<130mL/min 
Vancomycin continuous infusion 
 
Cl vanco (L/h) = 0.021 x ClCr (8h) (mL/m) + 2.3 
 
Perfusion Rate vanco (g/d) = Cl Vanco x 0,6 
 
                       Baptista ESICM 2013 
 
Dose of antibiotics 
  Vancomycin 
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Higher vancomycin doses and 
nephrotoxicity 
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Standard dose of vancomycin (n=220) 
High dose of vancomycin (n=26) 
*Nephrotoxicity: increase in creatinine ≥0.5 mg/dl 
Vancomycin dose 
Cmin, 
µg/ml 
Standard (<4 g/day)  9 
High (≥4 g/day)  18 
Time to nephrotoxicity for patients treated with vancomycin 
Lodise T Antimicrob Agents Chemother 2008;52:1330 
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MIC 
Time 
Cmax 
AUC 
T>MIC 
Vd 
Cl 
Healthy 
Vd 
Cl 
Time 
Cmax AUC 
MIC 
T>MIC 
Organ Failure 
Vd 
Cl 
MIC 
Time 
AUC 
T>MIC 
Cmax 
Sepsis 
Gonçalves-Pereira. Crit Care 2011, 15:R206 
Increased Vd 
 
 
 
Decreased Cl 
 Antibiotics Pharmacokinetics 
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Recommended dosing regimens in MODS 
Uldemollins, Chest 2011; 139:1210 
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Approach to Dose during Hemofiltration 
Choi. Blood Purif 2010;30:195 
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Dialysis Dialysis 
AG AG 
Dialysis 
Approach to Dose during Hemodialysis 
Aminoglycosides 
AG 
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An expert is someone who has stop 
thinking. He knows… 
  Frank Lloyd Wright  
